文章：

TCR-样 CARs和靶向新表位的TCR-CARs：一个新兴的潜力

TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential

原文发布日期：2021-03-02 

英文摘要：

Neoepitopes or neoantigens are a spectrum of unique mutations presented in a particular patient’s tumor. Neoepitope-based adoptive therapies have the potential of tumor eradication without undue damaging effect on normal tissues. In this context, methods based on the T cell receptor (TCR) engineering or chimeric antigen receptors (CARs) have shown great promise. This review focuses on the TCR-like CARs and TCR-CARs directed against tumor-derived epitopes, with a concerted view on neoepitopes. We also address the current limitations of the field to know how to harness the full benefits of this approach and thereby design a sustained and specific antitumor therapy. 

摘要翻译： 

新表位或新抗原是特定患者肿瘤中呈现的一系列独特突变。基于新表位的过继疗法具有根除肿瘤而不对正常组织造成不当损害的潜力。在此背景下，基于T细胞受体（TCR）工程或嵌合抗原受体（CAR）的方法已展现出巨大前景。本综述聚焦于针对肿瘤源性表位的TCR样CAR和TCR-CAR技术，并特别关注新表位的研究进展。我们同时探讨了该领域当前存在的局限性，以期充分把握这种方法的优势，从而设计出持续且特异性的抗肿瘤治疗方案。

原文链接：

TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential